Advisers to the U.S. Food and Drug Administration on Thursday unanimously voted in favor of targeting the same coronavirus strain for initial COVID-19 vaccine doses and boosters going forward, but some expressed skepticism about whether all Americans need to receive the shots annually. The agency is trying to simplify its COVID-19 vaccine policy as it considers whether to recommend Americans get an annual booster shot for the virus. Vaccine makers Pfizer Inc with partner BioNTech SE and Moderna Inc introduced late last year updated versions of their COVID vaccines tailored to target Omicron variants as well as the original coronavirus.
New data from one U.S. Centers for Disease Control and Prevention (CDC) database shows a possible stroke risk link for older adults who received an updated Pfizer /BioNTech COVID-19 booster shot, but the signal is weaker than what the agency had flagged earlier in January, health officials said on Thursday. U.S. Food and Drug Administration officials said they had not detected a link between the shots and strokes in two other safety monitoring databases. Earlier this month, U.S. health officials said they had detected the possible link to ischemic strokes in people over age 65 who received the newer booster shots in its Vaccine Safety Datalink (VSD) database.
Novo Nordisk's (NVO) top line is likely to have been driven by sales of its Diabetes and Obesity Care products in the fourth quarter of 2022.